CoChat
Sign Up
Cited by 25S100 Proteins and AnnexinsMedicinal Plant Extracts EffectsNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record.

Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat

Castagne, Vincent, Lemaire, Martine, Kheyfets, Irina, Dugina, Julia L, Sergeeva, Svetlana A, Epstein, Oleg I·2008·Journal of Pharmacy and Pharmacology
DOI 10.1211/jpp.60.3.0005
Open this paper in CoChat — free account

Abstract

S100 proteins are small calcium-binding proteins interacting with numerous intra- and extra cellular targets involved in diverse physiological functions. In particular, S100 proteins may be involved in the regulation of anxiety-related behaviour. In the present study, the effects of affinity-purified antibodies to S100 proteins administered orally at ultra-low doses were evaluated in pre-clinical tests for anxiolytic-like activity in the adult rat. In the Vogel conflict test in the rat, antibodies to S100 proteins increased punished drinking (anti-conflict effect) at 5 and 7.5 mL kg(-1), but not at 2.5 or 10 mL kg(-1). Antibodies to S100 proteins increased the percentage of entries into the open arms of an elevated plus-maze at 10 mL kg(-1), but not at lower doses. Taken together, these results indicate the presence of anxiolytic-like activity for antibodies to S100 proteins over the dose range 5-10 mL kg(-1) in the adult rat.

Overview

Integrity signals

Registry

Crossref · 10.1211/jpp.60.3.0005

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 57

  1. Ackermann, 2006, S100A1-deficient male mice exhibit increased exploratory activity and reduced anxiety-related responses, Biochim. Biophys. Acta., 1763, 1307, 10.1016/j.bbamcr.2006.08.048 · DOI
  2. Adami, 2004, S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain, Biochim. Biophys. Acta., 1742, 169, 10.1016/j.bbamcr.2004.09.008 · DOI
  3. Arcuri, 2005, S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation, J. Biol. Chem., 280, 4402, 10.1074/jbc.M406440200 · DOI
  4. Baker, 2003, The effects of homeopathic Argentum nitricum on test anxiety, Complement. Ther. Med., 11, 65, 10.1016/S0965-2299(03)00059-1 · DOI
  5. Bell, 2003, Harm avoidance, anxiety, and response to novelty in the adolescent S-100beta transgenic mouse: role of serotonin and relevance to Down syndrome, Neuropsychopharmacology, 28, 1810, 10.1038/sj.npp.1300242 · DOI
  6. Bellavite, 2006, Immunology and homeopathy. 2. Cells of the immune system and inflammation, Evid. Based Complement. Alternat. Med., 3, 13, 10.1093/ecam/nek018 · DOI
  7. Bellavite, 2006, Immunology and homeopathy. 3. Experimental studies on animal models, Evid. Based. Complement. Alternat. Med., 3, 171, 10.1093/ecam/nel016 · DOI
  8. Benfenati, 2004, S100A1 codistributes with synapsin I in discrete brain areas and inhibits the F-actin-bundling activity of synapsin I, J. Neurochem., 89, 1260, 10.1111/j.1471-4159.2004.02419.x · DOI
  9. Bonne, 2003, A randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder, J. Clin. Psychiatry, 64, 282, 10.4088/JCP.v64n0309 · DOI
  10. Businaro, 2006, S100B protects LAN-5 neuroblastoma cells against Aβ amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Aβ amyloid neurotoxicity at high doses, J. Neurosci. Res., 83, 897, 10.1002/jnr.20785 · DOI
  11. Castagné, 2006, Early behavioral screening for antidepressants and anxiolytics, Drug Dev. Res., 67, 729, 10.1002/ddr.20145 · DOI
  12. Chojnacka-Wojcik, 2005, The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action, J. Pharm. Pharmacol., 57, 253, 10.1211/0022357055399 · DOI
  13. Cialdella, 2001, [Homeopathic specialties as substitutes for benzodiazepines: double-blind vs. placebo study], Therapie, 56, 397
  14. Davidson, 1997, Homeopathic treatment of depression and anxiety, Altern. Ther. Health Med., 3, 46
  15. Dekeyne, 2000, The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents, Psychopharmacology (Berl.), 152, 55, 10.1007/s002130000449 · DOI
  16. Diehl, 2007, Long lasting sex-specific effects upon behavior and S100b levels after maternal separation and exposure to a model of post-traumatic stress disorder in rats, Brain Res., 1144, 107, 10.1016/j.brainres.2007.01.084 · DOI
  17. Donato, 2001, S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles, Int. J. Biochem. Cell Biol., 33, 637, 10.1016/S1357-2725(01)00046-2 · DOI · Paper page
  18. Donato, 2003, Intracellular and extracellular roles of S100 proteins, Microsc. Res. Tech., 60, 540, 10.1002/jemt.10296 · DOI · Paper page
  19. Epstein, 2003, Regulatory activity of ultralow doses, Bull. Exp. Biol. Med., 135, 8, 10.1023/A:1024715204972 · DOI
  20. Epstein, 2003, Membrane and synaptic effects of anti-S-100 are prevented by the same antibodies in low concentrations, Front. Biosci., 8, a79, 10.2741/1025 · DOI
  21. Epstein, 2006, Improvement of memory by means of ultra-low doses of antibodies to S-100B antigen, Evid. Based. Complement. Alternat. Med., 3, 541, 10.1093/ecam/nel073 · DOI
  22. File, 1999, Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function, Pharmacol. Biochem. Behav., 62, 695, 10.1016/S0091-3057(98)00208-1 · DOI
  23. Foell, 2007, S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules, J. Leukoc. Biol., 81, 28, 10.1189/jlb.0306170 · DOI
  24. Gebhardt, 2006, S100A8 and S100A9 in inflammation and cancer, Biochem. Pharmacol., 72, 1622, 10.1016/j.bcp.2006.05.017 · DOI · Paper page
  25. Graeff, 1998, The elevated T-maze as an experimental model of anxiety, Neurosci. Biobehav. Rev., 23, 237, 10.1016/S0149-7634(98)00024-4 · DOI
  26. Griebel, 1997, Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test, Pharmacol. Biochem. Behav., 57, 817, 10.1016/S0091-3057(96)00402-9 · DOI
  27. Handley, 1984, Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of ‘fear‘-motivated behaviour, Naunyn Schmiedebergs Arch. Pharmacol., 327, 1, 10.1007/BF00504983 · DOI
  28. Kilminster, 1999, Neuropsychological change and S-100 protein release in 130 unselected patients undergoing cardiac surgery, Stroke, 30, 1869, 10.1161/01.STR.30.9.1869 · DOI
  29. Kleindienst, 2006, A critical analysis of the role of the neurotrophic protein S100B in acute brain injury, J. Neurotrauma, 23, 1185, 10.1089/neu.2006.23.1185 · DOI
  30. Korfias, 2006, Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts, Curr. Med. Chem., 13, 3719, 10.2174/092986706779026129 · DOI
  31. Liappas, 2006, Effect of alcohol detoxification on serum S-100B levels of alcohol-dependent individuals, In Vivo, 20, 675
  32. Lomas, 2005, Best evidence topic report. S-100b protein levels as a predictor for long-term disability after head injury, Emerg. Med. J., 22, 889, 10.1136/emj.2005.031732 · DOI
  33. Loskutova, 2003, Efficiency of ultralow doses of antibodies to s100 protein and delta sleep-inducing peptide in rats with anxious depression, Bull. Exp. Biol. Med., 135, 20, 10.1023/A:1024797722719 · DOI
  34. Margis, 2004, Changes in S100B cerebrospinal fluid levels of rats subjected to predator stress, Brain Res., 1028, 213, 10.1016/j.brainres.2004.09.013 · DOI
  35. Mathie, 2006, Outcomes from homeopathic prescribing in medical practice: a prospective, research-targeted, pilot study, Homeopathy, 95, 199, 10.1016/j.homp.2006.06.002 · DOI
  36. Millan, 2003, The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines, Eur. J. Pharmacol., 463, 67, 10.1016/S0014-2999(03)01275-5 · DOI
  37. Moser, 1989, An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone, Psychopharmacology (Berl.), 99, 48, 10.1007/BF00634451 · DOI
  38. Moser, 1990, Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam, Br. J. Pharmacol., 99, 343, 10.1111/j.1476-5381.1990.tb14706.x · DOI
  39. Nutt, 2005, Overview of diagnosis and drug treatments of anxiety disorders, CNS Spectr., 10, 49, 10.1017/S1092852900009901 · DOI
  40. O'Dowd, 1997, Chicks injected with antisera to either S-100 alpha or S-100 beta protein develop amnesia for a passive avoidance task, Neurobiol. Learn. Mem., 67, 197, 10.1006/nlme.1997.3766 · DOI
  41. Oberbaum, 2003, Homeopathic treatment in emergency medicine: a case series, Homeopathy, 92, 44, 10.1054/homp.2002.0071 · DOI
  42. Pellow, 1985, Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat, J. Neurosci. Methods, 14, 149, 10.1016/0165-0270(85)90031-7 · DOI · Paper page
  43. Pilkington, 2006, Homeopathy for anxiety and anxiety disorders: a systematic review of the research, Homeopathy, 95, 151, 10.1016/j.homp.2006.05.005 · DOI
  44. Reali, 2005, S100b counteracts effects of the neurotoxicant trimethyltin on astrocytes and microglia, J. Neurosci. Res., 81, 677, 10.1002/jnr.20584 · DOI
  45. Rebaudo, 2000, Antiserum against S-100 protein prevents long term potentiation through a cAMP-related mechanism, Neurochem. Res., 25, 541, 10.1023/A:1007524412366 · DOI
  46. Santamaria-Kisiel, 2006, Calcium-dependent and -independent interactions of the S100 protein family, Biochem. J., 396, 201, 10.1042/BJ20060195 · DOI
  47. Scaccianoce, 2004, Relationship between stress and circulating levels of S100B protein, Brain Res., 1004, 208, 10.1016/j.brainres.2004.01.028 · DOI
  48. Senolt, 2006, S100A4 (Mts1): is there any relation to the pathogenesis of rheumatoid arthritis?, Autoimmun. Rev., 5, 129, 10.1016/j.autrev.2005.09.010 · DOI
  49. Sevar, 2005, Audit of outcome in 455 consecutive patients treated with homeopathic medicines, Homeopathy, 94, 215, 10.1016/j.homp.2005.07.002 · DOI
  50. Starostina, 1981, Studies on the interaction of Ca2+ ions with some fractions of the neurospecific S-100 protein, J. Neurochem., 36, 1904, 10.1111/j.1471-4159.1981.tb10814.x · DOI
  51. Stroick, 2006, Protein S-100B: a prognostic marker for cerebral damage, Curr. Med. Chem., 13, 3053, 10.2174/092986706778521751 · DOI
  52. Svenningsson, 2007, p11 (S100A10): an inducible adaptor protein that modulates neuronal functions, Curr. Opin. Pharmacol., 7, 27, 10.1016/j.coph.2006.10.001 · DOI
  53. Svenningsson, 2006, Alterations in 5-HT1B receptor function by p11 in depression-like states, Science, 311, 77, 10.1126/science.1117571 · DOI · Paper page
  54. Thiebot, 1976, Spécificité d'action des tranquilisants mineurs dans le test de l'escalier. Relation entre ces effets et leurs propriétés anxiolytiques, J. Pharmacol., 7, 87
  55. Vogel, 1971, A simple and reliable conflict procedure for testing anti-anxiety agents, Psychopharmacologia, 21, 1, 10.1007/BF00403989 · DOI
  56. Voronina, 2006, Antibodies to S-100 protein in anxiety-depressive disorders in experimental and clinical conditions, 137
  57. Westaby, 2000, Is there a relationship between serum S-100beta protein and neuropsychologic dysfunction after cardiopulmonary bypass?, J. Thorac. Cardiovasc. Surg., 119, 132, 10.1016/S0022-5223(00)70228-5 · DOI

Cited by

Sorted by citations

See all 25

Metadata

Authors
Castagne, V., Lemaire, M., Kheyfets, I., Dugina, J. L., Sergeeva, S. A., & Epstein, O. I.
Affiliations
  • Porsolt & Partners Pharmacology , 9 bis rue Henri Martin, 92100 Boulogne-Billancourt,
  • Porsolt (France) (FR)
  • NPF Materia Medica Holding, Research & Development Department , 3 rd Samotechniy per., 9, 127473, Moscow,
ORCID
Venue
Journal of Pharmacy and Pharmacology
Publisher
Oxford University Press (OUP)
Published
2008-03-01
Volume
60
Issue
3
Pages
309-316
ISSN
  • 0022-3573 (ISSN-L)
  • 2042-7158
DOI
10.1211/jpp.60.3.0005
OpenAlex
W2043537986
Cited by
25
References
0
Citations by year
2025: 2 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 1
FWCI
0.68
Type
journal article
Language
en
Open access
closed
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Journal of Pharmacy and Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
S-100 protein, immunoglobulins, anxiolytic-like activity, ultra-low dose, Vogel conflict test, elevated plus maze, anxiety-like behavior, calcium-binding proteins, dose-response relationship
MeSH terms
Administration, Oral, Animals, Antibodies, Anxiety, Conflict, Psychological, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Exploratory Behavior, Male, S100 Proteins, Anti-Anxiety Agents, Rats, Wistar, Maze Learning, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat. https://app.cochat.ai/papers/10.1211/jpp.60.3.0005
The paper
Castagne, V., Lemaire, M., Kheyfets, I., Dugina, J. L., Sergeeva, S. A., & Epstein, O. I. (2008). Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat. Journal of Pharmacy and Pharmacology. https://doi.org/10.1211/jpp.60.3.0005